Absci (ABSI) is back in focus after interim Phase 1 data for its ABS-201 program indicated favorable safety, tolerability, and pharmacokinetics, along with a recent $100 million funding round anchored by Eli Lilly.
See our latest analysis for Absci.
Absci’s recent news is landing against a backdrop of sharp share price swings, with a 30-day share price return of 11.54% and a 90-day gain of 81.96%, while the 1-year total shareholder return is 262.50% and the 3-year total shareholder return is very large. This suggests momentum has been building around its transition to a clinical-stage story and the Eli Lilly-backed funding.
If Absci’s recent move has your attention, this could be a good moment to see what else is moving in healthcare AI and antibody design by scanning 40 healthcare AI stocks
After Absci’s sharp share price move and Lilly’s backing, the real tension now is whether most of the repricing has already happened or if today’s valuation still leaves meaningful upside ahead for new money.
Most Popular Narrative: 32.6% Undervalued
Absci's most followed narrative pegs fair value at about $13.78 versus the last close of $9.28, which frames the recent move as only part of the story.
Disciplined capital allocation away from ABS-101 and into ABS-201, combined with a cash runway into the first half of 2028, allows Absci to progress multiple high value shots on goal. This improves the risk reward profile of future earnings relative to the current valuation.
Read the complete narrative. Read the complete narrative.
Curious what underpins that fair value gap for Absci. The narrative leans heavily on rapid revenue expansion, margin uplift and a rich future earnings multiple, and examines how those pieces fit together.
Result: Fair Value of $13.78 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Absci’s story still hinges on early stage ABS-201 data and a single lead asset focus, so any clinical setback or trial delay could quickly challenge this fair value case.
Find out about the key risks to this Absci narrative.
Next Steps
With both risks and rewards in play around Absci, it may be useful to review the situation promptly and confirm the details for yourself, starting with the 1 key reward and 3 important warning signs
Looking for more investment ideas beyond Absci?
If Absci has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to quickly spot other opportunities that match your style and risk comfort.
- Explore potential upside by scanning quality companies that look attractively priced through the 50 high quality undervalued stocks.
- Support your income stream by reviewing companies with higher yields via the 12 dividend fortresses.
- Emphasise resilience by focusing on companies that score well for financial strength using the solid balance sheet and fundamentals stocks screener (50 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com